# Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment

> **NCT04625699** · PHASE2 · WITHDRAWN · sponsor: **Catherine Shu**

## Conditions studied

- Nonsmall Cell Lung Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT04625699
- **Lead sponsor:** Catherine Shu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-12
- **Primary completion:** 2023-07
- **Final completion:** 2023-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Contract was never finalized.
- **Last updated:** 2023-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04625699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04625699, "Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04625699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*